Show simple item record

dc.contributor.authorKaradoğan, Dilek
dc.contributor.authorÖnal, Özgür
dc.contributor.authorKanbay, Yalçın
dc.date.accessioned2020-06-24T08:07:26Z
dc.date.available2020-06-24T08:07:26Z
dc.date.issued2019en_US
dc.identifier.citationKaradoğan, D., Önal, Ö., & Kanbay, Y. (2019). How does reimbursement status affect smoking cessation interventions? A real-life experience from the Eastern Black Sea region of Turkey. Tobacco induced diseases, 17(5), doi: 10.18332/tid/100412.en_US
dc.identifier.urihttps://doi.org/10.18332/tid/100412
dc.identifier.urihttps://hdl.handle.net/11494/2117
dc.description.abstractINTRODUCTION In the last decade, outpatient smoking cessation clinics (SCCs) in Turkey have been extended countrywide. Initially, only counseling was covered under health insurance. In 2011 and 2015, free varenicline and bupropion preparations were distributed to SCCs, periodically. In the current study we aimed to compare outcomes between the free and paid medication periods.en_US
dc.description.abstractMETHODS Patients applied to the local SCC in a secondary health care unit between June 2014 and June 2017. They were evaluated for SC interventions and had phone visits after their third month; these records were included in the study. Patients were grouped and evaluated according to medication's reimbursement status: free medication period (FP) and paid medication period (PMP).en_US
dc.description.abstractRESULTS In total, 733 patients applied to the SCC, 77.7% of them had applied during the FP. Analyses were made involving 417 patients who had records of third-month phone visit. Mean age of the patients was 44.0 +/- 13.7 years with the majority of patients (65%) being male. Sociodemographic characteristics of patients in both groups were not statistically different, while the percentage of patients with comorbid diseases was lower in the FP group (p<0.05). Treatment choices were different-the bupropion-prescribed group's rate was similar in both periods (53.5% in PMP vs 52.0% in FP), however varenicline was mostly prescribed in the FP (35.8% vs 14.1%) while nicotine replacement therapy was mostly prescribed in the PMP (32.4% vs 12.1%) (p<0.05). Patients who used the advised treatment for at least 30 days (treatment adherent) and the rate of quitters at the third month were higher in FP (p<0.05) from univariate analysis, however these differences were not statistically significant when a multivariate analysis was performed.en_US
dc.description.abstractCONCLUSIONS Our study showed that the free medication period increased the quit attempts but the increased in treatment adherence and quit success of the participating smokers was not obvious.en_US
dc.language.isoengen_US
dc.publisherEuropean Publishingen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectReimbursementen_US
dc.subjectSmoking cessationen_US
dc.subjectInsurance coverageen_US
dc.subjectTreatment adherenceen_US
dc.subjectQuit successen_US
dc.titleHow does reimbursement status affect smoking cessation interventions? A real-life experience from the Eastern Black Sea region of Turkeyen_US
dc.typearticleen_US
dc.relation.journalTobacco Induced Diseasesen_US
dc.departmentAÇÜ, Sağlık Bilimleri Fakültesien_US
dc.authorid0000-0001-6514-2120en_US
dc.identifier.volume17en_US
dc.identifier.issue5en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.18332/tid/100412en_US
dc.contributor.institutionauthor[0-Belirlenecek]en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record